Pulmonary Or Respiratory Drug Delivery Market Report 2025

The pulmonary or respiratory drug delivery market size has grown strongly in recent years. It will grow from $69.83 billion in 2024 to $75.67 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing prevalence of asthma, rising adoption of advanced inhalation devices, growth in healthcare expenditure globally, rising awareness of respiratory diseases, and rising incidence of allergic conditions.

The pulmonary or respiratory drug delivery market size is expected to see strong growth in the next few years. It will grow to $105.32 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising demand for personalized medicine, rising prevalence of chronic respiratory diseases, growing emphasis on telemedicine, increasing investments in healthcare infrastructure, and growth in e-commerce for pharmaceutical products. Major trends in the forecast period include advancements in particle engineering, development of advanced nebulizers, development of liposomal formulations, advancements in computational fluid dynamics, development of smart inhalers.

The forecast of 8.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. hospitals by increasing the cost of vibrating mesh nebulizers and smart inhaler technologies sourced from Sweden and Japan, thereby reducing treatment efficacy and elevating respiratory therapy equipment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of pneumonia is expected to drive the growth of the pulmonary or respiratory drug delivery market. Pneumonia is a lung infection that causes inflammation in the air sacs, which may fill with fluid or pus, resulting in symptoms such as cough, fever, and difficulty breathing. Factors contributing to the increasing prevalence of pneumonia include aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the rise of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery helps treat pneumonia by directly delivering medications such as antibiotics, bronchodilators, or anti-inflammatory agents to the lungs, enabling quicker and more effective treatment to alleviate symptoms, reduce inflammation, clear infections, and improve respiratory function, thus aiding recovery and preventing complications. For example, in November 2023, the Centre for Tropical Medicine and Global Health reported a significant rise in pneumonia cases in Kenya, reaching 793,864 in the 2022/2023 period. As such, the increasing prevalence of pneumonia is driving the pulmonary or respiratory drug delivery market's growth.

Companies in the pulmonary or respiratory drug delivery market are focusing on innovations such as complex drug delivery systems that improve treatment efficacy and patient compliance. Complex drug delivery systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, boosting drug effectiveness and patient outcomes. For example, in July 2023, Viatris Inc., a US-based healthcare company, and Kindeva Drug Delivery L.P., a US-based company specializing in drug delivery, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. Approved by the US Food and Drug Administration, this is the first generic version of AstraZeneca's Symbicort and combines budesonide and formoterol in a metered-dose inhaler for treating asthma and chronic obstructive pulmonary disease. It is available in two strengths, 80 micrograms and 160 micrograms, with 4.5 micrograms of formoterol.

In June 2022, Kindeva Drug Delivery acquired iPharma Labs Inc. for an undisclosed amount. This acquisition enhances Kindeva's capabilities in inhalation therapy development, allowing for improved formulation and manufacturing processes for respiratory medications. It also enables the company to offer comprehensive support to pharmaceutical clients from early-stage development to commercial production. iPharma Labs Inc. is a US-based company that specializes in pulmonary or respiratory drug delivery solutions.

Major players in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc.

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary or respiratory drug delivery report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmonary or respiratory drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pulmonary or respiratory drug delivery market consists of sales of metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, aerosol formulations, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pulmonary or respiratory drug delivery market research report is one of a series of new reports that provides pulmonary or respiratory drug delivery market statistics, including pulmonary or respiratory drug delivery industry global market size, regional shares, competitors with a pulmonary or respiratory drug delivery market share, detailed pulmonary or respiratory drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary or respiratory drug delivery industry. This pulmonary or respiratory drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary or respiratory drug delivery involves the direct administration of medication into the lungs to facilitate quick absorption, targeted treatment, and minimize systemic side effects, offering both local and systemic therapeutic benefits.

The primary categories of pulmonary or respiratory drug delivery include formulation type and device type. Formulation type pertains to the method of preparing drugs for efficient delivery, ensuring precise dosing and absorption in the body. Different canister options include plain and coated canisters, which are utilized for treating conditions such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and others. These devices are commonly used across various settings, including hospitals, clinics, and home care environments.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.